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Abstract. Cancer stem cells (CSCs) are considered to be 
the cause of tumor initiation, metastasis and recurrence. 
Additionally, CSCs are responsible for the failure of chemo-
therapy and radiotherapy. The isolation and identification of 
CSCs is crucial for facilitating the monitoring, therapy or 
prevention of cancer. We aimed to identify esophageal squa-
mous cell carcinoma (ESCC) stem-like cells, the epigenetic 
mechanism and identify novel biomarkers for targeting ESCC 
CSCs. Sixty-three paired ESCC tissues and adjacent non-
cancerous tissues were included in this study. CD271, which 
was identified as the CSC marker for melanoma, was assessed 
using quantitative PCR (qPCR). Using flow cytometry, we 
isolated CD271+ cells comprising 7.5% of cancer cells from 
the KYSE70 cell line. Sphere formation and anchorage-inde-
pendent growth were analyzed in CD271+ and CD271- cancer 
cells, respectively. qPCR was used to detect stem-related 
genes and CCK-8 was performed to analyze the sensitivity to 
chemotherapy in the two groups. Bisulfite genomic sequencing 
was used to analyze the methylation status. CD271 expression 
was significantly higher in ESCC tissues than in adjacent 
non-cancerous tissues. Compared with CD271- cancer cells, 
CD271+ cancer cells showed a higher ability of sphere and 
colony formation, a high level expression of stem-related gene, 
and resistance to chemotherapy. The expression of CD271 
was induced by a demethylation agent. In conclusion, CD271+ 
ESCC cells possess stem-like properties. CD271 can poten-
tially act as a prognostic marker for ESCC, whose expression 
is regulated epigenetically.
Introduction
Esophageal squamous cell carcinoma (ESCC) is a lethal 
malignancy with a 5-year survival rate of 26.2% due to late 
diagnosis, rapid growth and metastasis (1). Thus, it is neces-
sary to identify new effective therapeutic strategies for ESCC, 
especially molecularly targeted therapies, based on a better 
understanding of the biological events of ESCC cells. Cancer 
stem cells (CSCs) are a limited number of cancer cells with 
a self-renewal potential and extensive proliferation capacity 
and play a dominant role in tumor initiation, metastasis and 
recurrence (2-4). In pancreatic cancer, a subpopulation of 
migrating CD133+CXCR4+ CSCs was reported to be essen-
tial for tumor metastasis (5). In glioma, CD133+ CSCs were 
associated with radioresistance and contributed to tumor 
recurrence after radiotherapy due to preferential activating 
DNA damage checkpoint response. In malignant melanoma, 
the drug transporter and chemoresistance mediator ABCB5 
was identified as a novel molecular marker for a distinct 
subset of chemoresistant, stem-cell phenotype-expressing 
tumor cells, indicating that ABCB5 may be a specific target 
to enhance cytotoxic efficacy (6). Zhang et al also provided 
evidence that CSC-like cells may play a role in the progression 
and drug resistance of bladder cancer (7). The aforementioned 
studies showed that CSCs can be a good therapeutic target for 
various types of cancer. Although CSCs are common many 
types of tumors (8-11), the data for CSCs from human ESCC 
are conflicting.
CD271, a member of the tumor necrosis factor receptor 
superfamily (12), plays a role in cell proliferation, survival, 
and apoptosis (13). It is also known as a nerve growth factor 
receptor and interacts with neurotrophins (14). CD271+ cells 
have been reported to be genuine CSCs in human mela-
noma (15). CD271+ cells showed higher tumorigenecity and 
metastatic ability in melanoma (16). The high level of CD271 
expression was correlated with a poor prognosis for patients 
with hypopharyngeal cancer (17). Okumura et al suggested 
CD271 as the human esophageal keratinocyte stem cell 
marker, which may be valuable for prospectively investigating 
stem cell regulation in association with different biological 
processes including the neoplastic transformation of regenera-
tive epithelia (18). Authors of that study also identified CD271 
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as being expressed in 49.2% ESCC and necessary for survival 
and maintenance of ESCC tumors (19). huang et al demon-
strated that CD271+ cells possess some characteristics of CSCs 
(20). however, there is no report with regard to the epigenetic 
regulation on CD271 expression.
In the present study, we confirmed that CD271+ ESCC 
cells exhibited higher self-renewal ability and chemoresis-
tance. CD271 expression was associated with TNM stage and 
metastatic capacity in human ESCC and we found that CD271 
expression was regulated by DNA methylation. Our results 
showed that CD271+ ESCC cells possess stem-like properties 
and their expression is epigenetically regulated.
Materials and methods
Cell line and tissue specimens. The KYSE70 ESCC cell 
line was preserved in our laboratory and maintained in 
RMPI-1640 supplemented with 10% fetal bovine serum (both 
from hyclone, Logan, UT, USA), 100 U/ml of penicillin, and 
100 µg/ml of streptomycin at 37˚C, 5% CO2. Sixty-three paired 
ESCC tissues and adjacent non-cancerous tissues were previ-
ously collected and stored (2008-2010). Tissues were provided 
by the Department of Pathology, The first Affiliated hospital 
of Zhengzhou University, with confirmed histopathological 
results. Information pertaining to clinicopathological param-
eters were also available.
Flow cytometric analysis and cell sorting. Adherent KYSE70 
cells were trypsinized and dissociated into single cells 
suspended in PBS with 3% fetal bovine serum. The cells 
were stained with PE-conjugated mouse anti-human CD271 
monoclonal antibody (BD Biosciences, San Jose, CA, USA). 
The corresponding isotype immunoglobulins were used as 
controls. Dead cells were identified using 7-AAD (Biolegend, 
San Diego, CA, USA). Samples were analyzed using BD fACS 
Canto II cytometer (BD Biosciences) and sorted with a Moflo 
XDP cytometer (Beckman, Brea, CA, USA).
RNA extraction and cDNA synthesis. Total RNA was extracted 
from KYSE70 cells and tissue specimens by TRIzol reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer's instructions. The first-strand cDNA was 
synthesized from 1 µg of total RNA using PrimeScript RT 
reagent kit with gDNA Eraser (Takara, Shiga, Japan).
Quantitative real-time PCR. The cDNA was used as a template 
to detect the expression of CD271 in KYSE70 cells and tissue 
specimens. qPCR was performed using SYBR Premix Ex 
Taq II (Takara) and assessed by Agilent Mx3005P. GAPDh 
was used as an internal control. The data were analyzed by 
2-ΔΔCt. Primer sequences for qPCR are shown in Table I.
Sphere formation assay. The sorted CD271+ and CD271- cells 
were resuspended in DMEM/f12 medium (Invitrogen Life 
Technologies) supplemented with 4 µg/ml heparin (Sigma, 
St. Louis, MO, USA), B27 (1:50, Gibco, Life Technologies, 
Carlsbad, CA, USA), 20 ng/ml EGf, 20 ng/ml basic fGf (both 
from PeproTech, Rocky hill, NJ, USA), penicillin 100 IU/
ml and streptomycin 100 µg/ml and then seeded in 24-well 
ultra-low cluster plates (Corning Costar, Corning, NY, USA). 
After culturing for 7 days, the number of spheres was counted 
under a microscope (Leica, Wetzlar, Germany).
Anchorage-independent cell growth. The sorted CD271+ and 
CD271- cells (2x103 cells/well) were suspended in complete 
medium containing 0.6% low-melting-point agar (Sigma) 
and then applied to the top of a 1.2% agar/complete medium 
layer in six-well plates. After 14 days, surviving colonies were 
stained with 0.4% crystal violet (Sigma) and counted under a 
microscope (Leica, USA). The experiments were carried out 
in triplicate wells. Representative images were taken.
Drug sensitivity assay and chemotherapy resistance assay. 
5-fluorouracil (5-fU) and Cisplatin (DDP), both from Sigma, 
were dissolved according to the manufacturer's instructions. The 
sorted CD271+ and CD271- cells were seeded at 3x103 cells/well 
in 96-well plates and treated with chemotherapeutic reagents in 
quadruplicate. Cell viability was evaluated using CCK-8 assay 
(Biyuntian, Jiangsu, China) following treatment with chemo-
therapeutic reagents for 48 h, and the absorbance was measured 
at 450 nm using Multiskan Mk3 (Thermo fisher Scientific, San 
Jose, CA, USA). The percentage of survival in treated cells was 
normalized with untreated controls.
KYSE70 cells were continuously treated with DDP 
(0.5 µM) and 5-fU (0.5 µg/ml) until significant DDP and 5-fU 
resistance in KYSE70 cells was observed via cell viability 
assessment. flow cytometry was then used to detect the 
CD271 expression.
Bisulfite modification and methylation analysis. Genomic 
DNA extracted from the KYSE70 cell line using the Takara 
MiniBEST Universal Genomic DNA Extraction kit (Takara), 
was modified by sodium bisulfite using the epiTect Bisulfite 
kit (Qiagen, Germany) according to the manufacturer's instruc-
tions. Methylation status was analyzed by bisulfite genomic 
sequencing (BSP) of the Cpg islands. The region was amplified 
using the primers shown in Table i. Amplified products were 
cloned into pMD-18T simple vector (Takara), transformed into 
Dh5α competent cells (Takara), and plated under ampicilin 
selection. five independent clones were sequenced.
Statistical analysis. Data were expressed as mean ± SD and 
analyzed using the Student's t-test. Paired t-test was used 
for paired samples. Non-parametric test was performed for 
samples of non-normal distribution. Statistical analyses were 
conducted with SPSS 17.0 software. P<0.05 was considered to 
indicate a  statistically significant difference.
Results
CD271 expression is associated with stage and lymph node 
metastasis in human ESCC specimens. CD271 is considered 
crucial to maintain tumorigenecity and stem-like properties of 
cancer cells including melanoma, hypopharyngeal cancer and 
esophageal cancer. We compared the expression of CD271 in 
paired human ESCC specimens and adjacent non-cancerous 
tissues. As shown in fig. 1A, qPCR analysis revealed frequent 
upregulation of CD271 mRNA expression in carcinoma tissues 
compared with adjacent non-cancerous tissues, indicating that 
CD271 may act as an oncogene in human ESCC. Moreover, 
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the expression of CD271 was significantly correlated with 
TNM stage and lymph node metastasis but not other variables 
such as age, gender and differentiation (fig. 1B-D).
CD271+ cells overexpress stem-related gene NANOG and 
EMT markers. To study the stem cell-like properties of isolated 
CD271+ cells from the KYSE70 eSCC cell line, we first detected 
Table I. Primer sequences for qPCR for all the genes tested.
Gene name  Sequence Product size (bp)
qPCR
  GAPDh-f GCACCGTCAAGGCTGAGAAC 138
  GAPDh-R TGGTGAAGACGCCAGTGGA
  CD271-f AACAAGACCTCATAGCCAGCA 119
  CD271-R CAGGATGGAGCAATAGACAGG
  NANOG-f CAAAGGCAAACAACCCACTT 158
  NANOG-R TCTGCTGGAGGCTGAGGTAT
  fIBRO-f CAGTGGGAGACCTCGAGAAGA 169
  fIBRO-R GTCCCTCGGAACATCAGAAAC 
  VIM-f GAGAACTTTGCCGTTGAAGC 163
  VIM-R GCTTCCTGTAGGTGGCAATC
  BAK-f CATCAACCGACGCTATGACTC 192
  BAK-R GTCAGGCCATGCTGGTAGAC
  CASP3-f AGAACTGGACTGTGGCATTGAG 191
  CASP3-R GCTTGTCGGCATACTGTTTCAG
  CASP9-f CTCAGACCAGAGATTCGCAAAC 116
  CASP9-R GCATTTCCCCTCAAACTCTCAA
BSP
  CD271-Bf GAGAGAGAGAGGGTTGAAATTAG  505
  CD271-BR AAACATCCTAAATTCCAACAAA
qPCR, quantitative polymerase chain reaction; BSP, bisulfite genomic sequencing.
figure 1. The expression of CD271 is associated with stage and lymph node metastasis in human ESCC specimens. (A) The mRNA expression of CD271 was 
investigated in paired human ESCC specimens (T) and adjacent non-cancerous tissues (N) by qPCR. The correlation of CD271 expression with clinicopatho-
logical characteristics such as (B) stage, (C) lymph node metastasis and (D) differentiation was analyzed.
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the CD271 expression by flow cytometric analysis. We found 
the CD271+ subpopulation was 7.5% present in the KYSE70 
cell line (fig. 2A). CD271+ and CD271- cells were then sorted 
separately and the purity of the two sorted subpopulations was 
98.36 and 99.41%, respectively (fig. 2B). qPCR was used to 
confirm the expression of CD271 in the two subpopulations 
(fig. 2C). We also compared the expression of the stem-related 
gene NANOG, EMT markers fibronectin (fIBRO) and 
Vimentin (VIM), and apoptosis genes BAK, Caspase 3 and 
Caspase 9 in CD271+ and CD271- cells. Our results showed 
that compared with CD271- cells, CD271+ cells exhibited an 
increased expression of NANOG, fIBRO, VIM (fig. 2D-f) 
and a decreased expression of BAK, Caspase 3 and Caspase 9 
(fig. 2G).
CD271+ cells form more self-renewing spheres and promote 
anchorage-independent growth. One of the most important 
properties of GSCs is self-renewal. We examined the tumor 
sphere formation ability, which represents a self-renewal 
capacity. The sorted CD271+ and CD271- cells were seeded in 
24-well ultra-low cluster plates at a density of 5x103 cells/ml in 
DMEM/f12 medium supplemented with heparin, B27, EGf, 
and bfGf. After culturing for 7 days, CD271+ cells exhib-
ited a marked ability for tumor sphere formation, compared 
with CD271- cells (fig. 3A and B). In addition, CD271+ cells 
promoted anchorage-independent growth (fig. 3C), indicating 
that the CD271+ cells play an important role in the maintenance 
of malignant growth of ESCC cells. These results suggested 
that CD271+ ESCC cells possess stem-like properties.
CD271+ cells possess the ability to resist conventional chemo-
therapeutic reagents in vitro. Cancer stem cells are more 
resistant to conventional chemotherapeutic drugs. To examine 
whether the self-renewing CD271+ cells possess the hypoth-
esized CSC chemoresistant ability, the sensitivity of the sorted 
CD271+ and CD271- cells to DDP and 5-fU, respectively, was 
analyzed. The survival rates of CD271+ cells were higher under 
the treatment of DDP and 5-fU, compared with CD271- cells 
(fig. 4A and B). We also identified CD271+ stem-like cells could 
be enriched in DDP- and 5-fU-resistant cells (fig. 4C-G). The 
results validated a role for CD271+ cells in chemoresistance, 
which may explain the failure of current therapies to eradicate 
progenitors and prevent tumor recurrence.
CD271 expression is regulated by DNA methylation. 
Transcription factors and epigenetic modifications often guide 
external signals to a specific genetic response. We examined 
whether epigenetics including DNA methylation are involved 
in regulating CD271 expression. To investigate promoter 
methylation of CD271, BSP was performed. The area of 
the CpG-rich region spanning 31 CpG sites, was sequenced 
(fig. 5A). We found most CpG dinucleotides were methylated 
figure 2. CD271+ cells express high levels of stem-related gene nAnOg and eMT markers. (A) CD271 expression in KYSe70 was detected by flow cytometry. 
Of the cells 7.5% intensely expressed CD271. (B) The purity of sorted CD271+ and CD271- cells was 99.41 and 98.36%, respectively. (C) Quantitative real-time 
PCR analysis of CD271 expression in sorted CD271+ and CD271- cells. In the two subpopulations, relative expression of (D) NANOG, (E) fibronectin (fIBRO), 
(f) Vimentin (VIM) and (G) apoptosis genes BAK, Caspase 3 and Caspase 9 was analyzed by qPCR.
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figure 3. CD271+ cells form more self-renewing spheres and promote anchorage-independent growth. (A and B) The capability of tumor sphere formation was 
measured in sorted CD271+ and CD271- cells. (C) Anchorage-independent soft-agar growth was analyzed in sorted CD271+ and CD271- cells. 
figure 4. CD271+ cells possess the ability to resist to conventional chemotherapeutic reagents in vitro. Surviving cells were detected in sorted CD271+ and 
CD271- cells treated with (A) DDP and (B) 5-fU by CCK8 assay. CD271 expression was analyzed in (D and f) DDP-, (E and G) 5-fU-resistant cells and 
(C) parent cells by flow cytometry.
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in KYSE70 cells (fig. 5B). To elucidate whether the meth-
ylation of CD271 was associated with its expression, KYSE70 
cells were treated with 5-aza (an inhibitor of the methylase 
enzyme, which can reactivate mRNA expression suppressed 
by methylation) for 6 days and performed BSP and qPCR to 
detect the promoter methylation and expression of CD271. 
following treatment with 5 µM 5-aza for 6 days, CD271 gene 
exhibited an obvious induction and the promoter methylation 
level was reduced (fig. 5C and D), suggesting that the expres-
sion of CD271 is regulated by DNA methylation.
Discussion
The majority of ESCC patients present with an advanced stage 
at the time of diagnosis, with poor prognosis, rapid growth 
and spread due to late diagnosis. Accumulating evidence 
suggested the CSCs theory in that tumorigenic potential is 
largely restricted to CSCs (21,22). CSCs from tumor tissues 
or established cancer cell lines can be isolated by cell-surface 
markers expressed on CSCs (17,23). In recent studies ALDh 
was identified as the CSC marker for various types of cancer 
including ovarian (24), breast (25), lung (26) and prostate (27) 
cancer, CD44+CD24- for breast (28) and ovarian (29) cancer, 
CD133 for non-small cell lung (30), liver (31) and lung (32) 
cancer. however, Meng et al reported that both CD133+ and 
CD133- subpopulations contain similar numbers of CSCs (33). 
Therefore, identification of specific cell-surface markers to 
define CSCs is important for the possible establishment of 
target-specific therapies using small molecule inhibitors or 
humanized antibodies.
CD271 knockdown was found to eliminate the capacity 
of melanoma cells to form heterogeneous tumors most 
likely through the downregulation of mediators for 
melanoma invasion and metastasis (GLI-2, SOX2 and 
ERBB3), angiogenesis (IGfBP-2), proliferation (fST and 
MITf) or chemoresistance (RhOJ) (34). CD271 was also 
identified as a predominant molecule responsible for the 
proliferation, tumorigenecity and plasticity of melanoma 
cells. Accumulating evidence has shown that metastases 
develop when distant organs are seeded with CSCs derived 
from a primary tumor (35). Boiko et al identified that 
CD271+ melanoma cells lacked the expression of TYR, 
MART1 and MAGE genes in 86, 69 and 68% of melanoma 
patients, respectively, which may explain the reason for T-cell 
figure 5. CD271 expression is regulated by DNA methylation. (A) CD271 promoter region. The analyzed CpG dinucleotides are underlined. Primers used 
for bisufilte genomic sequencing are in bold. Methylation status of 31 Cpg sites in the promoter region of KYSe70 cells treated (B) without or (C) with 
demethylation agent 5-aza. (D) qPCR analysis of CD271 expression in KYSE70 cells treated with or without 5-aza. 
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therapies targeting these antigens usually resulting in only 
temporary tumor shrinkage (16). Okumura et al have shown 
that CD271 expression correlated with negative lymph node 
metastasis and lower TnM staging. There was no significant 
correlation between CD271 expression and distant metastasis 
in ESCC (19). however, in this study we show that the expres-
sion of CD271 was significantly higher in eSCC tissues than 
adjacent non-cancerous tissues. in contrast to findings of a 
previous study (19), we found that the overexpression of 
CD271 was significantly associated with TNM stage and 
lymph node metastasis. Taken together, these data strongly 
suggest CD271 as an oncogene that plays an important role in 
ESCC progression.
Cell sorting yielded CD271+ and CD271- cells and identi-
fied the overexpression of the stem-related gene NANOG 
in CD271+ cells. Since EMT plays a key role in tumor inva-
sion and metastasis during tumor progression, we tested the 
expression of EMT markers between the two subpopulations. 
As expected, CD271+ cells highly expressed mesenchymal 
markers, such as fIBRO and VIM. We also found that CD271+ 
cells were able to form more tumor spheres and colonies 
compared with CD271- cells. Our results further showed that 
CD271+ cells exhibited general resistance to DDP and 5-fU, 
with higher survival percentages compared with CD271- cells. 
Taken together, these data suggest that CD271 is a marker of 
stem-like cells in ESCC. In addition, we observed increased 
CD271+ cells in DDP- and 5-fU-resistant cells. In other words, 
conventional chemotherapeutic drugs, such as DDP and 5-fU, 
may selectively decrease the CD271- population, resulting in a 
relative increase of CD271+ cell frequency. Thus, CSCs can be 
responsible for treatment failures of chemotherapy and poor 
clinical outcomes.
Accumulating evidence has suggested that CSCs are not 
only governed by genetic alterations but also aberrant epigen-
etic regulation. Sun et al reported that a unique set of genes such 
as NANOG, OCT4 and SOX9, were demethylated in invasive 
cancer cells but methylated in non-invasive cancer cells, indi-
cating that they may be biologically important in the invasive 
population and upregulated during the EMT process (36). 
Schirmer et al (39) found that the gene L1CAM, which can 
promote cell motility, invasion and metastasis formation in 
various human cancers (37-39), could be induced by treatment 
with the demethylation agent 5-aza in endometrial carcinoma 
cell lines (40). We previously found that tumor-suppressor 
gene SPINT2 was induced by a demethylation agent (41). This 
shows that following epigenetic drug treatment, hypermeth-
ylated tumor-suppressor genes as well as oncogenes may be 
activated simultaneously. in the present study, we firstly found 
CD271 was regulated epigenetically and its expression could 
be induced by demethylation agent treatment. Therefore, 
epigenetic therapy may be a ‘double-edge sword’ and unex-
pected side effects may occur.
In conclusion, we have demonstrated that CD271, the ESCC 
cancer stem cell marker, is a potential prognostic marker of 
patients with ESCC and is regulated epigenetically.
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